Reactions 1680, p231 - 2 Dec 2017 Extremities tremor and dizziness: 3 case reports In a retrospective cohort analysis, 3 patients [ages and sexes not stated] were described, who developed dizziness or extremities tremor during treatment with mexiletine [dosages, routes, duration of treatment to reactions onsets and outcomes not stated]. The patients, with recurrent ventricular tachyarrhythmia, were started on daily doses of mexiletine. One patient developed extremities tremor and one patient developed dizziness. The patients were continued on the mexiletine therapy. One patient developed severe dizziness, after which the mexiletine therapy was stopped. Author comment: "In four (23.5%) patients, mild temporary side effects were observed, which did not require discontinuation of therapy. . . (in one patient extremities tremor, in one patient dizziness)." "Only in three (17.6%) patients severe side effects of mexiletine treatment occurred. . . (in one patient severe dizziness)." Sobiech M, et al. Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks. Kardiologia Polska 75: 1027-1032, No. 10, 2017. Available from: URL: http://doi.org/10.5603/KP.2017.0189 - Poland 803284536 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera